Market Overview

Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients With Myasthenia Gravis; Says Both Doses of Tirasemtiv Were Well Tolerated

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News

 

Related Articles (CYTK)